医学
重要事件
2型糖尿病
糖尿病
梅德林
重症监护医学
内分泌学
政治学
历史
考古
法学
标识
DOI:10.1016/s2213-8587(22)00351-5
摘要
New therapies come slowly for type 1 diabetes, so the approval of teplizumab by the USA Food and Drug Administration (FDA) marks a milestone. The drug itself, a humanised anti-CD3 monoclonal antibody, delays clinical type 1 diabetes in at-risk individuals and is the first approved disease-modifying drug for type 1 diabetes.
科研通智能强力驱动
Strongly Powered by AbleSci AI